Stocks and Investing
Stocks and Investing
Tue, May 18, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Chris Shibutani Initiated (BNTX) at Hold and Held Target at $173 on, May 18th, 2021
Chris Shibutani of Goldman Sachs, Initiated "BioNTech SE" (BNTX) at Hold and Held Target at $173 on, May 18th, 2021.
Chris has made no other calls on BNTX in the last 4 months.
There are 3 other peers that have a rating on BNTX. Out of the 3 peers that are also analyzing BNTX, 2 agree with Chris's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Daina Graybosch of "SVB Leerink" Maintained at Hold with Increased Target to $159 on, Tuesday, May 11th, 2021
- Olga Smolentseva of "Bryan Garnier" Downgraded from Strong Buy to Hold and Increased Target to $206 on, Tuesday, May 11th, 2021
This is the rating of the analyst that currently disagrees with Chris
- Arlinda Lee of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $240 on, Thursday, May 13th, 2021
Contributing Sources